Skip to main content
NIH funding notice RFA-AI-20-019

Rational Design of Vaccines Against Hepatitis C Virus (U19 Clinical Trial Not Allowed)

Closed on June 15, 2020.

Posted
February 24, 2020
Close date
June 15, 2020
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

3 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $7,028,555 in first-year total cost, median $2,377,023.

Most frequent study sections

  1. Special Emphasis Panel[ZAI1 FDS-M (J1)]3

Most frequent institutions

  1. EMORY UNIVERSITY1
  2. JOHNS HOPKINS UNIVERSITY1
  3. STANFORD UNIVERSITY1
Competing awards under RFA-AI-20-019 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2021Mechanisms of spontaneous and vaccine mediated hepatitis C virus control to direct rational development of a novel HCV vaccine1U19AI159822-01COX, ANDREA LJOHNS HOPKINS UNIVERSITY, MD$2,632,704ZAI1
2021A vaccine design to induce protective B and T cell immunity against hepatitis C virus1U19AI159840-01FOUNG, STEVENSTANFORD UNIVERSITY, CA$2,377,023ZAI1
2021Correlates of protective immunity to HCV and rational vaccine design1U19AI159819-01GRAKOUI, ARASHEMORY UNIVERSITY, GA$2,018,828ZAI1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.